Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

This study has been completed.
University of Virginia
Information provided by:
National Center for Research Resources (NCRR) Identifier:
First received: April 6, 2000
Last updated: June 23, 2005
Last verified: December 2003

April 6, 2000
June 23, 2005
January 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00005104 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome
Not Provided


I. Determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene citrate in women with polycystic ovary syndrome.

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are randomized to one of two treatment arms.

Patients receive oral metformin or oral placebo three times daily for 7 weeks. Patients remaining anovulatory by day 49 receive metformin or placebo plus escalating doses of oral clomiphene citrate daily for 5 consecutive days, beginning on days 50, 80, and 110. Following ovulation, treatment with clomiphene citrate and metformin or placebo continues until 6 ovulatory cycles occur, pregnancy occurs, or anovulation persists. Patients receiving the placebo arm who have not ovulated on the highest dose of clomiphene citrate may be crossed over to receive metformin after a 6 week washout.

Not Provided
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
  • Polycystic Ovary Syndrome
  • Hyperinsulinism
  • Drug: clomiphene citrate
  • Drug: metformin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided


--Disease Characteristics--

Patients with chronic anovulation due to polycystic ovary syndrome (PCOS) who have failed clomiphene citrate

Must have oligoovulation and hyperandrogenemia

--Prior/Concurrent Therapy--

Endocrine therapy: At least 2 months since prior clomiphene citrate


  • At least 2 months since prior standard therapy (including over the counter drugs)
  • At least 2 months since prior investigational drugs
  • Prior multi/prenatal vitamins allowed

--Patient Characteristics--

Hematopoietic: Hematocrit greater than 38%


  • Liver function normal
  • No clinically significant hepatic disease


  • No clinically significant renal disease
  • Creatinine less than 1.4 mg/dL
  • No proteinuria

Cardiovascular: No clinically significant cardiac disease

Pulmonary: No clinically significant pulmonary disease


  • Thyroid function normal
  • Prolactin normal
  • Estradiol normal
  • Fasting 17 alpha-hydroxy progesterone less than 200 ng/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency


  • Not pregnant
  • Negative pregnancy test
  • Male partner must have a normal semen analysis by WHO criteria
  • Must be in acceptable health by interview, medical history, physical exam, and laboratory tests
  • No diabetes mellitus
  • No clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease
  • No clinically significant malignant disease except nonmelanomatous skin cancer
  • At least 1 year since any prior drug abuse or alcoholism
18 Years to 40 Years
Contact information is only displayed when the study is recruiting subjects
United States,   Italy
199/14915, UVA-HIC-7538, UVA-WSE026
Not Provided
Not Provided
National Center for Research Resources (NCRR)
University of Virginia
Study Chair: William S. Evans University of Virginia
National Center for Research Resources (NCRR)
December 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP